Human CD254/RANKL/TNFSF11 Recombinant Protein (N-His)
- Catalog number: PH10085
- Availability: In Stock
$211.00
- Ex Tax: $211.00
- Description: Recombinant Human CD254/RANKL/TNFSF11 Protein, N-His (PH10085) expressed in E. coli, spanning Tyr69-Asp317. Purity: >90% by SDS-PAGE.
Highlights:
• His-Tagged — N-terminal 6×His tag for IMAC purification.
• E. coli Expression — High-yield, cost-effective production.
• High Purity — >90% purity verified by SDS-PAGE. - Form: Lyophilized
- Storage buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
- Purity: >90% as determined by SDS-PAGE.
- Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
- Endotoxin level: Please contact with the lab for this information.
- Expression system: E. coli
- Protein length: Tyr69-Asp317
- Predicted molecular weight: 30.67 kDa
- Stability and Storage: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
- Reconstitution: Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
- Alternative Names: ODF, TNF-related activation-induced cytokine, Osteoclast differentiation factor, TNFSF11, TRANCE, Osteoprotegerin ligand, RANKL, Tumor necrosis factor ligand superfamily member 11, Receptor activator of nuclear factor kappa-B ligand, CD254, OPGL
- Species: Homo sapiens (Human)
- Shipping: In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
- Background: Tumor necrosis factor ligand superfamily member 11 (CD254/RANKL) is a ~35 kDa protein. Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. CD254 is the therapeutic target of denosumab (Prolia).
References:
1. Luan, X. et al. (2012) Journal of immunology (Baltimore, Md. : 1950) 189, 245-52. PMID: 22664871 - Note: For research use only.
Images
-
SDS-PAGESDS-PAGE for Recombinant Human CD254/RANKL/TNFSF11 Protein, N-His.
